CMT Drug Development Process and Therapy Pipeline

Therapies Under Development in Industry

Therapy Pipeline

SMALL MOLECULE
SMALL MOLECULE
SMALL MOLECULE
SMALL MOLECULE
SMALL MOLECULE
SMALL MOLECULE
CLINICAL TRIALS
CLINICAL TRIALS
CLINICAL TRIALS
COMPANY
NAME
CMT TYPE
DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
APPROVED
Applied Therapeutics
AT 007 (aldose reductase inhibitor)
Biallelic SORD mutations
NMD Pharma
NMD670
1 and 2
InFlectis BioScience
IFB-088
1A, 1B, 1E
CKD Pharmaceuticals (Novartis)
CKD-510 (HDAC6 inhibitor)
1 and 2
Augustine Therapeutics*
AGT100216
1 and 2
Oryzon Genomics*
HDAC6 inhibitor
1A
Actio Biosciences
TRPV4 modulator
2C
Mitochondria in Motion
Mitofusion activators
2A
Mitochondria Emotion
MiM111 & CPR1 (Mitofusion activators)
2A
Samsara Therapeutics*
SAM1196 peripheral (autophagy enhancer)
1A
AcuraStem** (Takeda)
PIKfyve inhibitor
4B1
Lmito Therapeutics
LMT801
1A
MitoR Therapeutics
MTRX
2A
Avicenna
ROCK inhibitor (AV-016)
2A
Alesta Therapeutics
ALE2 (kinase inhibitor)
2D
Asha Therapeutics*
ASHA-623
2A
Recursion Pharmaceuticals
Drug screen (undisclosed)
2A
AcuraStem*
Drug screen (undisclosed)
2A
ReviR Therapeutics
RTX-117
Broad
HDAX Therapeutics
HDAC6 inhibitor
2
GENE THERAPY
GENE THERAPY
GENE THERAPY
GENE THERAPY
GENE THERAPY
GENE THERAPY
CLINICAL TRIALS
CLINICAL TRIALS
CLINICAL TRIALS
COMPANY
NAME
CMT TYPE
DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
APPROVED
Helixmith
Engensis (VM202)
1A
Alcyone Therapeutics
ACTX technology (Gene replacement; AAV9-IGHMBP2)
2S
Sarepta Therapeutics
scAAV1.tMCK.NTF3
1A
lonis
Gene knockdown; ASO
1A
MAASiRNA
Gene knockdown; siRNA-squalene
1A
Toolgen
TGT-001 (Gene editing; CRISPR/Cas9)
1A
Nervosave Therapeutics
NVO-101 (Gene knockdown; siRNA)
1A
Novartis (DTx Pharma)*
EKD060
1A
Armatus Bio***
ARM-101 (Gene knockdown; miRNA)
1A
Elpida Therapeutics***
ELP-02 (Gene replacement; AAV9)
4J
Vanda Pharmaceuticals
VCA-894A
2S
XIRNA Bio*
Gene replacement
2D
Shift Pharmaceuticals*
Gene knockdown;
PMO-ASO
1A
Nanite*
Polymer nanoparticle delivery (Gene knockdown; PMO-ASO)
1A
OTHER BIOLOGICS
OTHER BIOLOGICS
OTHER BIOLOGICS
OTHER BIOLOGICS
OTHER BIOLOGICS
OTHER BIOLOGICS
CLINICAL TRIALS
CLINICAL TRIALS
CLINICAL TRIALS
COMPANY
NAME
CMT TYPE
DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
APPROVED
ENCell
EN001
1A
Orthogonal Neuroscience
ORT247 (mAb inhibitor of EphA4 receptors)
1 and 2
Cellatoz Pharmaceuticals
CLZ-2002/T-SC
1A
Ageronix SA
AAT (plasma derived Alpha1-Antitrypsin)
1A

*Funded by CMTRF
**CMTRF funded underlving technology
***CMTRF funded drug manufacturing

Updated 7/2025

Today, available treatments for CMT are designed to help people effectively manage disease symptoms. Drugs may be used to lessen pain, and orthopedic surgery to correct joint deformities. Physical and occupational therapy often incorporate strength training, muscle and ligament stretching and exercise to help with muscle weakness and pain. In addition, a range of medical devices including braces, walkers and wheelchairs are used to help maintain mobility, assisted ventilation can help with breathing issues and hearing aids help compensate for hearing loss.

However, with the identification over the past several decades of more than 100 different gene mutations underlying the various forms of CMT, scientists now have a broad range of targets at which to aim therapies that can modify the course of the disease.

CMTRF is working hard today to make good on our promise to deliver safe and effective treatments to people living with all forms of CMT. Our expectation is that the treatments of tomorrow will do more than manage symptoms. Tomorrow’s treatments, under development and testing now, will aim to modify the course of the disease whether by targeting a particular function, or changing a person’s genetic makeup.

Take Action